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Liraglutide has pleiotropic effects favouring cardiovascular and renal risks. We investigated indi-
vidual responses to liraglutide in six cardio-renal risk factors to examine whether responses in one
risk factor are associated with changes in other risk factors (cross-dependency). We performed
secondary analysis of the LIRA-RENAL trial (n = 279) in type 2 diabetes. HbA1c, body weight,
systolic blood pressure (SBP), low density lipoprotein (LDL)-cholesterol, urine albumin-to-
creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR) were measured at baseline
and after 26 weeks of liraglutide/placebo treatment: “Good responders” had a change within the
best quartile. In the liraglutide-treated group, good HbA1c responders showed similar changes in
other risk factors analysed to low responders (P ≥ 0.17). Good body weight responders had a
larger reduction in HbA1c than low body weight responders (−1.6 ± 0.94 vs. –1.0 ± 0.82%;
P = 0.003), but similar changes in the other risk factors (P ≥ 0.11). Good and low responders in
SBP, UACR, LDL-cholesterol or eGFR showed similar changes in other risk factors (P ≥ 0.07).
Treatment response to liraglutide is largely individual; aside from an association between body
weight and HbA1c reduction, there are no obvious cross-dependencies in risk factor response.
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1 | INTRODUCTION
Several newer antihyperglycaemic drugs have pleiotropic effects1
favouring cardiovascular and renal risk in type 2 diabetes.
Liraglutide, a once-daily human glucagon-like peptide-1 (GLP-1)
analogue, lowers glucose, body weight, blood pressure, lipids and
albuminuria.2–4 The long-term Liraglutide Effect and Action in Diabe-
tes: Evaluation of Cardiovascular Outcome Results (LEADER) clinical
trial established that liraglutide reduces cardiovascular events and
offers long-term renoprotection in patients with type 2 diabetes and
established cardiovascular disease.5
We explored the pleiotropic effects of liraglutide on an individual
level in the Efficacy and Safety of Liraglutide versus Placebo as Add-
on to Glucose-Lowering Therapy in Patients with Type 2 Diabetes
and Moderate Renal Impairment (LIRA-RENAL) study. We
investigated individual responses to liraglutide in six cardio-renal risk
factors (HbA1c, body weight, systolic blood pressure [SBP], low den-
sity lipoprotein [LDL]-cholesterol, urine albumin-to-creatinine ratio
[UACR] and estimated glomerular filtration rate [eGFR]) to examine
whether beneficial responses in one risk factor are associated with
changes in other risk factors (cross-dependency).
2 | MATERIALS AND METHODS
2.1 | Study design and participants
A secondary analysis of LIRA-RENAL, which was a 26-week, random-
ized, double-blind, placebo-controlled, parallel group trial, aimed to
assess superiority of liraglutide 1.8 mg versus placebo as an add-on to
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existing glucose-lowering treatment (oral glucose-lowering agents
and/or insulin therapy) in participants with type 2 diabetes and mod-
erate renal impairment (stage 3 chronic kidney disease, defined as
eGFR of 30-59 mL/min/1.73m2). Patients were to maintain their
background diabetes medication throughout the trial but the dose of
insulin or sulphonylurea could be reduced in case of hypoglycaemic
episodes.6
The study was conducted according to the Declaration of Helsinki
and was approved by the relevant authorities. Trial registration:
ClinicalTrials.gov identifier NCT01620489.
2.2 | Measurement of risk factors
HbA1c, body weight, SBP, LDL-cholesterol and UACR were measured
and eGFR was calculated (based on the Modification of Diet in Renal
Disease [MDRD] formula) at baseline, at regular intervals during the
trial, and after 26 weeks of treatment, using routine methods.6 UACR
was calculated as the mean of the morning urine samples from the
day before the visit and the day of the visit.
2.3 | Statistical analyses
Good response was defined as an observed change from baseline
(ratio to baseline for UACR and LDL-cholesterol) at week 26 at or
below the first quartile of the distribution in the liraglutide group (ie,
greatest reduction). For eGFR, good response was defined as an
observed ratio to baseline at or above the third quartile of the distri-
bution in the liraglutide group (ie, increase or smallest reduction).
We evaluated separately in the liraglutide and placebo groups the
association of good response among the six risk factors using Fisher's
exact test.
Furthermore, we evaluated (a) linear correlations among changes
in the six risk factors to investigate treatment response on a continu-
ous scale, and (b) associations between baseline values and responder
status for each of the six risk factors in the liraglutide-treated group.
Within each treatment group, a two-sample t-test using Sat-
terthwaite's approximation was used to compare good and low
responders for each risk factor in terms of both baseline values and
change from baseline in the other risk factors. Pairwise associations in
change from baseline among the six risk factors were also evaluated
using scatterplots, and Pearson's correlation coefficients were
calculated.
For all analyses, LDL-cholesterol, UACR and eGFR values were
log-transformed. Because all analyses are exploratory, no correction
for multiplicity was applied.
3 | RESULTS
Of 279 participants exposed to study medication, 220 who had at
least one of the six variables measured at baseline and after 26 weeks
of liraglutide (n = 109) or placebo (n = 111) treatment were included
in the present analysis.
Participants had a mean ± standard deviation (SD) age of 66.7
(±8.5) years, diabetes duration of 15.0 (±8.3) years, and 48.6%
were female. At baseline, mean (±SD) HbA1c was 8.0 (±0.8)%,
body weight 94.6 (±17.7) kg and SBP 136 (±15) mm Hg. Partici-
pants had a geometric mean (coefficient of variation) UACR of 7.1
(6.6) mg/mmol, LDL-cholesterol of 2.3 (0.5) mmol/L and eGFR of
47.2 (0.2) mL/min/1.73m2. Baseline characteristics (Supporting
Information Table S1) were generally well balanced by treatment
group.
3.1 | Cross-dependency for response in risk factors
Changes in risk factors for good versus low responders, for the
liraglutide-treated participants, are presented in Table 1. Good (reduc-
tion ≥1.7%) and low HbA1c responders showed similar changes from
baseline to end of trial in other risk factors analysed (P ≥ 0.17;
Figure 1A). Good body weight responders (reduction ≥4.6 kg) had a
significantly larger reduction in HbA1c than low body weight
responders (P = 0.003), but similar changes in the other risk factors
(Figure 1B). No significant difference was seen between good and low
responders in SBP (reduction ≥10 mm Hg), UACR (≤54% of baseline
value), LDL-cholesterol (≤85% of baseline value) or eGFR (≥107% of
baseline value) from baseline to end of trial in any of the other risk
factors (P ≥ 0.07).
Results for good versus low responders in the six risk factors, for
placebo-treated participants, are presented in Supporting Information
Table S2. Overall, findings were similar to the liraglutide-treated
group, with few associations between changes in the six risk factors.
We further investigated whether a good response in one risk fac-
tor was associated with good response in each of the other risk fac-
tors, using the cut-offs stated for a good response. Results of these
analyses of binary response variables were largely consistent with the
analyses of continuous change from baseline (Supporting Information
Table S3A and B).
3.2 | Linear correlations between changes in the six
risk factors
We analysed linear correlation between observed changes in the six
risk factors after 26 weeks of treatment with liraglutide. HbA1c
reduction was associated with body weight reduction (r = 0.24;
P = 0.01) but changes in the other risk factors were not significantly
correlated (P ≥ 0.11).
3.3 | Association between baseline value and
response for each risk factor
For each risk factor, we analysed the association between the baseline
value and response to liraglutide treatment. This association was sig-
nificant for HbA1c (P < 0.001), SBP (P < 0.001) and LDL-cholesterol
(P = 0.002), but not for body weight, eGFR or UACR (P ≥ 0.051).
4 | DISCUSSION
Liraglutide treatment has pleiotropic effects that favourably change
both cardiovascular and renal risk variables. We observed no obvi-
ous cross-dependency in the risk factor response, except for
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association of a good response in body weight with a greater reduc-
tion in HbA1c. The same association was not seen among placebo-
treated patients.
We have recently published data from a small study (n = 31)
examining the pleiotropic effects of liraglutide. Surprisingly, a pro-
nounced body weight loss was not associated with a greater reduction
in HbA1c, and a pronounced reduction in HbA1c was not associated
with a greater reduction in urinary albumin excretion rate. We had
expected a cross-dependency between reduction in SBP and urinary
albumin excretion rate, but this was also not seen.7 With the obvious
limitations of a small open-label study, we wished to confirm our
findings.
The present analysis of LIRA-RENAL confirms the highly individ-
ual treatment response to liraglutide. Aside from a good response in
body weight being associated with a greater reduction in HbA1c,
there was no obvious cross-dependency in risk factor response in the
liraglutide-treated group. Overall changes in the placebo group were
smaller (vs. the liraglutide group) but, interestingly, there were several
cross-dependencies in risk factor response in this group, suggesting
that the population size and length of study were sufficient to detect
possible associations. An HbA1c reduction following body weight
reduction may be more evident over time, and therefore we speculate
that the longer study duration in LIRA-RENAL (26 weeks vs. 7 weeks
for the open-label study) may partly explain this observed difference.
The association was not seen in the placebo-treated group.
We had originally hypothesized that in some individuals liraglutide
treatment would lead to a response in all risk factors, whereas other
individuals would not respond in any risk factor. Our findings, from
analysing cross-dependency in liraglutide response in two different
populations with type 2 diabetes, do not support this hypothesis.
Individual characteristics may influence the magnitude of the
treatment response to liraglutide.8 We showed that a high baseline
level of HbA1c, SBP and LDL-cholesterol was associated with a
greater response in the corresponding variable. We acknowledge that
regression towards the mean can contribute to these associations.
Interestingly, a high baseline body weight was not linked to a good
body weight response. In accordance with our finding, Berkovic et al.
showed that higher baseline HbA1c was related to a greater reduction
in HbA1c after liraglutide treatment for 6 months in 207 participants
with type 2 diabetes.9
Studies showing the beneficial effect of GLP-1 receptor agonists
on hard outcomes are available, and future analysis of the link
between individual patient risk factor responses and occurrence of
renal and cardiovascular events could ultimately enhance the opportu-
nity to personalize treatment. Other mechanisms such as inflamma-
tion that are not directly reflected in the cardio-renal risk factors may
also be involved.
4.1 | Clinical implications
We found substantial heterogeneity in the individual risk factor
response to liraglutide treatment. This may help guide clinicians to not
just take into account treatment response in one variable (ie, HbA1c
or body weight), but to also consider a number of other variables
when assessing the effect of liraglutide, in anticipation of a beneficial
clinical outcome. Furthermore, a good response in one risk factor does
not appear to predict response in other variables, except for an associ-
ation between body weight and glycaemic control.
TABLE 1 Good versus low responders in risk factors for the
liraglutide-treated group
Variable Q4 Q1–Q3 P value
(A) HbA1c good versus low responders (Q4 [n = 29] vs. Q1–Q3 [n = 76])
HbA1c (%) −2.2 (0.48) −0.77 (0.67) —
Body weight (kg) −3.3 (3.4) −2.2 (3.8) 0.17
SBP (mm Hg) 1 (17) −3 (15) 0.28
UACR (%)a 0.81 [1.6] 0.91 [1.2] 0.67
eGFR (%)a 0.97 [0.17] 0.98 [0.18] 0.75
LDL-cholesterol (%)a 1.1 [0.29] 1.0 [0.31] 0.22
(B) Body weight good versus low responders (Q4 [n = 29] vs. Q1–Q3
[n = 77])
HbA1c (%) −1.6 (0.94) −1.0 (0.82) 0.003
Body weight (kg) −7.0 (2.3) −0.8 (2.5) —
SBP (mm Hg) −3 (15) −1 (15) 0.51
UACR (%)a 0.67 [1.1] 0.97 [1.3] 0.12
eGFR (%)a 0.98 [0.14] 0.98 [0.19] 0.99
LDL-cholesterol (%)a 1.0 [0.34] 1.0 [0.29] 0.89
(C) SBP good versus low responders (Q4 [n = 33] vs. Q1–Q3 [n = 73])
HbA1c (%) −1.1 (0.71) −1.2 (0.97) 0.69
Body weight (kg) −3.3 (3.8) −2.1 (3.7) 0.13
SBP (mm Hg) −18 (10) 6 (11) —
UACR (%)a 0.69 [1.1] 0.98 [1.4] 0.13
eGFR (%)a 0.97 [0.13] 0.98 [0.20] 0.94
LDL-cholesterol (%)a 1.0 [0.32] 1.0 [0.30] 0.81
(D) UACR good versus low responders (Q4 [n = 21] vs. Q1–Q3 [n = 61])
HbA1c (%) −1.4 (0.80) −1.0 (0.96) 0.17
Body weight (kg) −2.9 (3.8) −2.4 (3.9) 0.63
SBP (mm Hg) −3 (18) −0.3 (16) 0.57
UACR (%)a 0.29 [0.69] 1.3 [0.88] —
eGFR (%)a 0.98 [0.28] 0.96 [0.13] 0.79
LDL-cholesterol (%)a 1.0 [0.23] 1.0 [0.30] 0.69
(E) eGFR good versus low responders (Q4 [n = 27] vs. Q1–Q3 [n = 78])
HbA1c (%) −1.3 (0.89) −1.1 (0.89) 0.40
Body weight (kg) −2.4 (3.3) −2.6 (3.8) 0.82
SBP (mm Hg) 0 (16) −3 (15) 0.46
UACR (%)a 1.2 [2.5] 0.76 [0.87] 0.18
eGFR (%)a 1.20 [0.17] 0.91 [0.11] —
LDL-cholesterol (%)a 1.0 [0.29] 1.0 [0.31] 0.72
(F) LDL-cholesterol good versus low responders (Q4 [n = 24] vs. Q1–Q3
[n = 71])
HbA1c (%) −0.92 (0.77) −1.3 (0.87) 0.07
Body weight (kg) −2.9 (4.7) −2.7 (3.1) 0.88
SBP (mm Hg) −5 (13) −0.8 (16) 0.26
UACR (%)a 0.75 [1.4] 0.89 [1.3] 0.56
eGFR (%)a 0.95 [0.3] 0.99 [0.14] 0.56
LDL-cholesterol (%)a 0.71 [0.15] 1.16 [0.23] —
Abbreviations: eGFR, estimated glomerular filtration rate; LDL, low density
lipoprotein; SBP, systolic blood pressure; UACR, urine albumin-to-
creatinine ratio.
a Relative change of log-transformed values. Values are mean (standard
deviation) or geometric mean [coefficient of variation]. Two-sample
t-test using the Sattertwhaite approximation.
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4.2 | Strengths and limitations
The strength of this study is that we confirmed our previous findings
from a small open-label study7 in a secondary analysis of a large, ran-
domized, controlled trial. As this is still an exploratory analysis, however,
we cannot exclude the possibility that significant associations between
risk factor responses may exist. An important limitation is the day-to-
day variation in the cardio-renal risk factors, which could obscure a true
correlation among the risk factors. In particular, UACR, SBP and serum
creatinine vary from day to day and this variation may hamper detection
of a true correlation. The aim of the present analysis was to determine
cross-dependency in risk factor response. Future analyses of a dedi-
cated liraglutide outcome trial are required to assess if the changes in
risk factors translate into renal and cardiovascular events.
In conclusion, liraglutide treatment has pleiotropic effects that
favourably change cardiovascular and renal risk. We show that treat-
ment response to liraglutide is largely individual and, aside from an
association between body weight reduction and HbA1c reduction,
there are no obvious cross-dependencies in the risk factor response.
Future analysis of the link between risk factor responses and occur-
rence of renal and cardiovascular events could ultimately lead to
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FIGURE 1 Cross-dependency in risk factor response. A, Changes in risk factors for good versus low HbA1c responders for liraglutide-treated
participants. B, Changes in risk factors for good versus low body weight responders for liraglutide-treated participants. Good responders were
defined as having a change from baseline to week 26 within the best quartile in the liraglutide-treated group. Good responders in HbA1c
(reduction ≥1.7%) had similar changes in the other risk factors compared with low responders in HbA1c (P ≥ 0.17). Good body weight responders
had a significantly greater reduction in HbA1c (−1.6 ± 0.94 vs. –1.0 ± 0.82%) compared with low body weight responders (P = 0.003), but no
difference in change of other risk factors between responder groups (P ≥ 0.11). Observed mean ± standard error (SE). For log-transformed data
of low density lipoprotein (LDL)-cholesterol, urine albumin-to-creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR), observed
means and SE were calculated on the log-transformed values and then back-transformed to the original scale
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personalized treatment and help elucidate which effects are most
important for optimal outcomes.
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